H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.;UNIVERSITY OF SOUTH FLORIDA
发明人:
Mark MCLAUGHLIN,David L. MORSE,Shari Pilon-Thomas,Scott Antonia
申请号：
US16659207
公开号：
US20200188472A1
申请日:
2019.10.21
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the immune effector is an immune effector protein or an immune effector fragment thereof. The current invention also pertains to a method of treating a disease in a subject, the method comprising administering to the subject a pharmaceutically effective amount of the molecular conjugates of the current invention to the subject. The methods of the current invention can be used to treat cancer, such as breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, or melanoma.
